Amicus Therapeutics (FOLD) Reports Smaller Than Expected Q1 Loss; Revs Light
More News related to FOLD
- Amicus Therapeutics Appoints Margaret G. McGlynn, R.Ph., to Board of Directors
- Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Amicus Therapeutics Announces Third Quarter 2009 Financial Results Release Date
- Unusual 11 Mid-Day Movers 10/05: ROIAK, DEPO, AVII, CMLS Higher; FOLD, SGEN, SCLN, REED Lower
Amicus Therapeutics, Inc. (Nasdaq: FOLD) reports a Q1 non-GAAP loss of $0.46, 18 cents better than the analyst estimate of ($0.64). Revenue for the quarter was $4.61 million, versus the consensus of $6.34 million.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
